150 related articles for article (PubMed ID: 33433318)
1. Efficacy of ferumoxytol versus sodium ferric gluconate in anemia management in outpatient hemodialysis patients: A prospective cohort study.
El Nekidy WS; El-Masri MM; Kadri A; Soong DC
Clin Nephrol; 2021 Apr; 95(4):189-194. PubMed ID: 33433318
[TBL] [Abstract][Full Text] [Related]
2. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
4. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
Airy M; Mandayam S; Mitani AA; Chang TI; Ding VY; Brookhart MA; Goldstein BA; Winkelmayer WC
Nephrol Dial Transplant; 2015 Dec; 30(12):2068-75. PubMed ID: 26311216
[TBL] [Abstract][Full Text] [Related]
6. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
7. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
8. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
Kapoian T; O'Mara NB; Singh AK; Moran J; Rizkala AR; Geronemus R; Kopelman RC; Dahl NV; Coyne DW
J Am Soc Nephrol; 2008 Feb; 19(2):372-9. PubMed ID: 18216316
[TBL] [Abstract][Full Text] [Related]
9. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
[TBL] [Abstract][Full Text] [Related]
10. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
11. Iron indices and intravenous ferumoxytol: time to steady-state.
Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J
Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523
[TBL] [Abstract][Full Text] [Related]
12. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
13. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
14. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
[TBL] [Abstract][Full Text] [Related]
15. The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis.
Lacquaniti A; Gargano R; Campo S; Casuscelli di Tocco T; Schifilliti S; Monardo P
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374275
[No Abstract] [Full Text] [Related]
16. Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients.
Javier AM
Nephrol Nurs J; 2002 Apr; 29(2):183-6. PubMed ID: 11997953
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
Schiller B; Bhat P; Sharma A
Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
[TBL] [Abstract][Full Text] [Related]
18. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
20. Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
Coyne DW; Sims A; Bingel B
Nephrol Nurs J; 2008; 35(6):583-7. PubMed ID: 19260610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
